| | |
Survivin
|
XIAP
|
XAF1
|
|---|
| |
IHC score*
|
n
|
(%)
|
n
|
(%)
|
n
|
(%)
|
|---|
|
HCC
|
Negative
|
-
| |
7
|
17,5%
|
23
|
57,5%
|
| |
Low
|
22
|
55,0%
|
23
|
57,5%
|
17
|
42,5%
|
| |
High
|
18
|
45,0%
|
10
|
25,0%
|
-
| |
|
Adjacent liver#
|
Negative
|
-
| |
10
|
25,0%
|
21
|
52,5%
|
| |
Low
|
2
|
5,0%
|
19
|
47,5%
|
19
|
47,5%
|
| |
High
|
38
|
95,0%
|
11
|
27,5%
|
-
| |
|
Non-adjacent liver#
|
Negative
|
-
| |
12
|
30,0%
|
25
|
62,5%
|
| |
Low
|
1
|
2,5%
|
18
|
45,0%
|
15
|
37,5%
|
| |
High
|
39
|
97,5%
|
10
|
25,0%
|
-
| |
- The number (n) and the percentage of patients (%) in each IHC category are indicated.
- *Negative (score 0), Low (score 1–6) and High (score 7–12).
- #Adjacent liver: liver parenchyma at less than 1 cm from the tumor; non-adjacent liver: liver parenchyma at more than 3 cm from tumor.
